KISS1R and cancer: Our findings suggest that GPR54 or ERK5 deficient CAR‐T cells exert a favorable killing effect at low effector‐to‐target ratios and lower CAR‐T cell exhaustion, highlighting the promising clinical potential of GPR54 or ERK5 inhibition in CAR‐T cell immunotherapy for human cancer.